Triple
T6003749
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Loxo Oncology |
E133655
|
entity |
| Predicate | regulatoryAgencyApproval |
P16099
|
FINISHED |
| Object | U.S. Food and Drug Administration |
E13297
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: U.S. Food and Drug Administration | Statement: [Loxo Oncology, regulatoryAgencyApproval, U.S. Food and Drug Administration]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: U.S. Food and Drug Administration Context triple: [Loxo Oncology, regulatoryAgencyApproval, U.S. Food and Drug Administration]
-
A.
Food and Drug Administration
chosen
The Food and Drug Administration is a U.S. federal agency responsible for protecting public health by regulating food, drugs, medical devices, and other consumer products.
-
B.
Center for Biologics Evaluation and Research
The Center for Biologics Evaluation and Research is the U.S. regulatory body responsible for overseeing the safety, efficacy, and quality of biological products such as vaccines, blood products, and gene therapies.
-
C.
Center for Drug Evaluation and Research
The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
-
D.
Office of Regulatory Affairs
The Office of Regulatory Affairs is the U.S. FDA’s primary field organization responsible for inspecting regulated products and manufacturers, enforcing compliance, and overseeing import operations to protect public health.
-
E.
FDA CFSAN
FDA CFSAN is the U.S. Food and Drug Administration’s center responsible for regulating the safety, labeling, and nutritional quality of foods, dietary supplements, and cosmetics.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: regulatoryAgencyApproval Context triple: [Loxo Oncology, regulatoryAgencyApproval, U.S. Food and Drug Administration]
-
A.
hasRegulatoryApproval
Indicates that an entity has received formal authorization or clearance from a relevant regulatory authority to operate, be sold, or be used in a specified context.
-
B.
regulatingAgency
chosen
Indicates that one entity serves as the official authority responsible for overseeing, controlling, or enforcing rules and standards on another entity or activity.
-
C.
FDAApprovalType
Indicates the specific regulatory pathway or category under which a product has been approved by the U.S. Food and Drug Administration.
-
D.
regulatoryOutcome
Indicates the result or consequence of a regulatory process, such as approval, rejection, modification, or other formal decision made by a regulatory authority regarding an entity or action.
-
E.
regulatoryApprovalYear
Indicates the calendar year in which an official regulatory body granted approval for the referenced item, action, or entity.
- F. None of above.
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c00872444c8190bfaf1739dcec765c |
completed | March 22, 2026, 3:19 p.m. |
| NER | Named-entity recognition | batch_69c04f0f63148190826198281dce3713 |
completed | March 22, 2026, 8:20 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c1088f5c84819094e4696c24c4dd79 |
completed | March 23, 2026, 9:31 a.m. |
| PD | Predicate disambiguation | batch_69c049e3316c819087ea635fa7ee8472 |
completed | March 22, 2026, 7:58 p.m. |
Created at: March 22, 2026, 4:06 p.m.